title: Intermediate hepatocellular carcinoma: How to choose the best treatment modality?
abstract: Intermediate stage, or stage B according to Barcelona Clinic Liver Cancer classification, of hepatocellular carcinoma (HCC) comprises a heterogeneous population with different tumor burden and liver function. This heterogeneity is confirmed by the large variability of treatment choice and disease-relate survival. The aim of this review was to highlight the existing evidences regarding this specific topic. In a multidisciplinary evaluation, patients with large (> 5 cm) solitary HCC should be firstly considered for liver resection (LR). When LR is unfeasible, locoregional treatments are evaluable therapeutic options, being transarterial chemoembolization (TACE), the most used procedure. Percutaneous ablation can be an evaluable treatment for large HCC. However, the efficacy of all ablative procedures decrease as tumor size increases over 3 cm. In clinical practice, a combination treatment strategy [TACE or transarterial radioembolization (TARE)-plus percutaneous ablation] is "a priori" preferred in a relevant percentage of these patients. On the other hands, sorafenib is the treatment of choice in patients who are unsuitable to surgery and/or with a contraindication to locoregional treatments. In multifocal HCC, TACE is the first-line treatment. The role of TARE is still undefined. Surgery may have also a role in the treatment of multifocal HCC in selected cases (patients with up to three nodules, multifocal HCC involving 2-3 adjacent liver segments). In some patients with bilobar disease the combination of LR and ablative treatment may be a valuable option. The choice of the best treatment in the patient with intermediate stage HCC should be "patient-tailored" and made by a multidisciplinary team.
authors.affiliation: Giovan Giuseppe Di Costanzo, Raffaella Tortora, Department of Transplantion, Liver Unit, Cardarelli Hospital, 80131 Napoli, Italy.
authors.forename: Giovan Giuseppe
authors.initials: GG
authors.lastname: Di Costanzo
authors.affiliation: Giovan Giuseppe Di Costanzo, Raffaella Tortora, Department of Transplantion, Liver Unit, Cardarelli Hospital, 80131 Napoli, Italy.
authors.forename: Raffaella
authors.initials: R
authors.lastname: Tortora
keywords: Chemoembolization; Combination therapy; Hepatectomy; Hepatocellular carcinoma; Liver transplantation; Percutaneous ablation